If you opt to delay ASCT, your stem cells would still be collected and stored for use in the future. This is then followed by consolidation and/or maintenance therapy. If you are eligible and decide to proceed with a transplant, you will usually receive induction therapy followed by stem cell collection and storage, high-dose melphalan chemotherapy, and ASCT. If you are a candidate for transplant, you may choose to have a transplant after three or four cycles of induction therapy or you may decide to complete induction therapy and consider transplant later. Determining whether transplant is an option is an important factor in selecting induction therapy. One of the first questions that must be answered, by both you and your doctor, is whether you are a candidate for high-dose chemotherapy followed by an autologous stem cell transplant (ASCT). ![]() These include the features of your myeloma, the risk of side effects, convenience for you, and the familiarity of the doctor with the available treatment options. The choice of initial treatment depends on many factors. ![]() Three-drug regimens (triplet therapy) generally include an immunomodulatory drug (Revlimid or Pomalyst), a proteasome inhibitor (Velcade, Kyprolis, or Ninlaro), and a steroid (dexamethasone or, less commonly, prednisone).įour-drug regimens (quadruplet therapy) are similar to three-drug regimens but also include an anti-CD38 monoclonal antibody (Darzalex or Sarclisa). Induction therapy, or front-line therapy, typically consists of a three-drug or four-drug combination regimen given over three to four cycles, each of which typically lasts 3 or 4 weeks.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |